+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Prevalence of switching from two anti-TNF biosimilars back to biologic reference products in Germany




Prevalence of switching from two anti-TNF biosimilars back to biologic reference products in Germany




International Journal of Clinical Pharmacology and Therapeutics 57(6): 323-328



Biosimilars are becoming more and more important for the treatment of many diseases. However, it is not understood how they are tolerated. Our aim was to analyze the behavior of switching from two anti-TNF biosimilars back to biologic reference products in German patients. Patients switching from etanercept reference to an etanercept biosimilar between February 2016 and December 2017 and those switching from the infliximab reference product to an infliximab biosimilar between February 2015 and December 2017 were included in the study (index date). The main outcome of this study, the rate of switching from these two biosimilars back to reference products, was analyzed using Kaplan-Meier curves. A multivariate Cox regression model was used to predict the switch-back behavior. A total of 2,956 patients were included in this study. After 3 months, 14.7% and, after 12 months, 30.2% of them were switched back from a biosimilar to the reference product. Sex, age, physician specialty, and co-therapy were not significantly associated with this switch. Almost one third of the patients treated with one of two biosimilar drugs after previous biologic therapy are switched back to reference products in Germany.
.

(PDF emailed within 1 workday: $29.90)

Accession: 066695843

Download citation: RISBibTeXText

PMID: 30990409


Related references

Intended use of reference products & WHO International Standards/Reference Reagents in the development of similar biological products (biosimilars). Biologicals 39(5): 262-265, 2012

Switching Reference Medicines to Biosimilars: A Systematic Literature Review of Clinical Outcomes. Drugs 78(4): 463-478, 2018

Full Interchangeability in Regards to Immunogenicity Between the Infliximab Reference Biologic and Biosimilars CT-P13 and SB2 in Inflammatory Bowel Disease. Inflammatory Bowel Diseases 24(3): 465-466, 2018

Full Interchangeability in Regard to Immunogenicity Between the Infliximab Reference Biologic and Biosimilars CT-P13 and SB2 in Inflammatory Bowel Disease. Inflammatory Bowel Diseases 24(3): 601-606, 2018

Low back pain and lumbago-sciatica in nurses and a reference group of clerks: results of a comparative prevalence study in Germany. International Archives of Occupational and Environmental Health 75(7): 484-490, 2002

Switching Between Reference Biologics and Biosimilars for the Treatment of Rheumatology, Gastroenterology, and Dermatology Inflammatory Conditions: Considerations for the Clinician. Current Rheumatology Reports 19(6): 37, 2018

Biosimilars in oncology: a therapeutic alternative to the reference products?. Zeitschrift für Gastroenterologie 54(11): 1223-1229, 2016

Biopharmaceuticals: Reference Products and Biosimilars to Treat Inflammatory Diseases. Therapeutic Drug Monitoring 39(4): 308-315, 2017

Contribution of animal studies to evaluate the similarity of biosimilars to reference products. Drug Discovery Today 20(4): 483-490, 2016

Changes In The Prices Of Reference Biotechnology Products By The Penetration Of Biosimilars Into The Turkish Pharmaceutical Market. Value in Health 18(7): A535, 2015

Decrease in high on-treatment platelet reactivity (HPR) prevalence on switching from clopidogrel to prasugrel: insights from the switching anti-platelet (SWAP) study. Thrombosis and Haemostasis 109(2): 347-355, 2013

Occupations associated with a high risk of back pain: representative outcomes of a back pain prevalence study in the Federal Republic of Germany. Versicherungsmedizin 59(2): 67-72, 2007

Occupations associated with a high risk of self-reported back pain: representative outcomes of a back pain prevalence study in the Federal Republic of Germany. European Spine Journal 15(6): 821-833, 2006

Switching of biologic disease modifying anti-rheumatic drugs in patients with rheumatoid arthritis in a real world setting. Journal of Medical Economics 17(4): 259-265, 2015

The impact of reference pricing on switching behaviour and healthcare utilisation: the case of statins in Germany. European Journal of Health Economics 11(3): 267-277, 2010